Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07079735 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

Study acronym: VALET-CMV
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria revised Site details revised at 1 of 2 sites · Publications: details revised at 6 of 6 entries Show 2 more changesShow less
    • Site details revised at 1 of 2 sites
    • Publications: details revised at 6 of 6 entries
  2. Start date changed from estimate of Aug 17, 2025 to Sep 12, 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Trial Details
NCT Number NCT07079735
Lead Sponsor Columbia University
Collaborators: Cornell University
Conditions CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov